Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
- Conditions
- RSV Immunization
- Interventions
- Biological: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccineBiological: Streptococcus pneumoniae vaccineBiological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccineBiological: Measles, mumps, and rubella vaccineBiological: Varicella virus vaccineBiological: Placebo
- Registration Number
- NCT06397768
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Brief Summary
This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine \[Vaxelis® or Pentacel® and Recombivax HB®\] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.
- Detailed Description
The study duration is approximately 9 months for each participant.
* Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only
* Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only
* Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 2226
- Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)
- Participants who are healthy as determined by medical evaluation including medical history and physical examination
- For Cohort 1: Infant received doses of vaccines containing hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit
- Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, hepatitis B virus
- Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- History of medically diagnosed wheezing
- Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
- Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
- Member of a household that contains an immunocompromised individual, including, but not limited to:
- A person living with human immunodeficiency virus (HIV)
- A person who has received chemotherapy within the 12 months prior to study enrollment
- A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
- A person living with a solid organ or bone marrow transplant
- Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
- History of definitive contraindications to any of the concomitant vaccines that will be administered as part of the study protocol
- Participant's biological mother with previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding
- Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration
- Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment
- Receipt of immune globulins, blood or blood-derived products in the past 3 months
- Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
- Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study
- For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)
- For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)
- Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months) RSVt vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months) Placebo Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months) Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months) Varicella virus vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months) Placebo Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months) Streptococcus pneumoniae vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months) Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months) Streptococcus pneumoniae vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months) Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months) Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months) Streptococcus pneumoniae vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months) Placebo Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months) Streptococcus pneumoniae vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months) Measles, mumps, and rubella vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months) Placebo Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months) Varicella virus vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months) Measles, mumps, and rubella vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months) RSVt vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months) RSVt vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months) RSVt vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months) Hepatitis B vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months) Rotavirus vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months) Rotavirus vaccine Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months) Hepatitis B vaccine Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age
- Primary Outcome Measures
Name Time Method RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3 Day 85 Antibody titers at Day 85
RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3 Day 85 Antibody titers at Day 85
RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4 Day 113 Antibody titers at Day 113
RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4 Day 113 Antibody titers at Day 113
- Secondary Outcome Measures
Name Time Method Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2 Within 30 minutes after each study intervention administration Number of participants experiencing unsolicited systemic adverse events
Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2 28 days after the 12 month routine vaccinations Antibody 28 days after the 12 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by ECL Cohort 2 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2 28 days post-dose 2 Antibody titers 28 days post-dose 2
Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2 Throughout the study, approximately 9 months Number of participants experiencing SAEs
Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2 21 days after each IMP administration Number of participants experiencing solicited administration site reactions
Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL) 28 days after the 12 month routine vaccinations Antibody titers 28 days after the 12 month routine vaccinations
RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2 28 days post-dose 2 Antibody titers 28 days post-dose 2
Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2 21 days after each IMP administration Number of participants experiencing solicited systemic site reactions
Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2 Throughout the study, approximately 9 months Number of participants experiencing AESIs
RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2 Day 1 Antibody titers at Day 1
RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2 Day 1 Antibody titers at Day 1
Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2 Within 28 days after each study intervention administration Number of participants experiencing unsolicited AEs
Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2 Throughout the study, approximately 9 months Number of participants experiencing MAAEs
Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1 28 days after the 6 month routine vaccinations Antibody titers 28 days after the 6 month routine vaccinations
Trial Locations
- Locations (67)
Investigational Site Number : 4840004
🇲🇽Mexico City, Mexico
Investigational Site Number : 6300004
🇵🇷Trujillo Alto, Puerto Rico
South Alabama Medical Clinic- Site Number : 8400065
🇺🇸Grand Bay, Alabama, United States
Kaiser Permanente - Sierra Gardens- Site Number : 8400063
🇺🇸Roseville, California, United States
Kaiser Permanente - Point West Medical Offices- Site Number : 8400064
🇺🇸Sacramento, California, United States
Velocity Clinical Research - Sioux City- Site Number : 8400054
🇺🇸Sioux City, Iowa, United States
Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007
🇺🇸Birmingham, Alabama, United States
MedPharmics - Mobile - Dauphin Street- Site Number : 8400017
🇺🇸Mobile, Alabama, United States
Alliance Research Institute- Site Number : 8400040
🇺🇸Bell Gardens, California, United States
Kaiser Permanente - San Jose Medical Center- Site Number : 8400060
🇺🇸San Jose, California, United States
Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062
🇺🇸Walnut Creek, California, United States
NOLA Research Works- Site Number : 8400044
🇺🇸New Orleans, Louisiana, United States
MedPharmics - Biloxi- Site Number : 8400011
🇺🇸Biloxi, Mississippi, United States
QPS Bio-Kinetic Clinical Applications- Site Number : 8400046
🇺🇸Springfield, Missouri, United States
Boeson Research - Missoula- Site Number : 8400006
🇺🇸Missoula, Montana, United States
Velocity Clinical Research - Hastings- Site Number : 8400016
🇺🇸Hastings, Nebraska, United States
Dayton Clinical Research- Site Number : 8400030
🇺🇸Dayton, Ohio, United States
Ohio Pediatrics - Dayton- Site Number : 8400033
🇺🇸Dayton, Ohio, United States
Senders Pediatrics- Site Number : 8400022
🇺🇸South Euclid, Ohio, United States
PAS RESEARCH- Site Number : 8400035
🇺🇸Edinburg, Texas, United States
Houston Clinical Research Associates- Site Number : 8400013
🇺🇸Houston, Texas, United States
Matrix Clinical Research - Huntington Park- Site Number : 8400018
🇺🇸Huntington Park, California, United States
Velocity Clinical Research - Washington DC- Site Number : 8400050
🇺🇸Washington, District of Columbia, United States
Kaiser Permanente - Oakland Medical Center- Site Number : 8400047
🇺🇸Oakland, California, United States
PAS Research- Site Number : 8400005
🇺🇸Tampa, Florida, United States
University of Kentucky Chandler Medical Center- Site Number : 8400051
🇺🇸Lexington, Kentucky, United States
Boeson Research - Great Falls- Site Number : 8400041
🇺🇸Great Falls, Montana, United States
Square-1 Clinical Research- Site Number : 8400031
🇺🇸Erie, Pennsylvania, United States
Tribe Clinical Research - 525 Verdae Boulevard- Site Number : 8400012
🇺🇸Greenville, South Carolina, United States
South Texas Clinical Research- Site Number : 8400004
🇺🇸Corpus Christi, Texas, United States
UTHealth Houston- Site Number : 8400037
🇺🇸Houston, Texas, United States
DM Clinical Research - Houston - Jones Road- Site Number : 8400052
🇺🇸Houston, Texas, United States
Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045
🇺🇸Houston, Texas, United States
University of Texas Medical Branch at Galveston- Site Number : 8400057
🇺🇸League City, Texas, United States
Maximos Ob/Gyn- Site Number : 8400024
🇺🇸League City, Texas, United States
Pediatric Center - Richmond- Site Number : 8400032
🇺🇸Richmond, Texas, United States
North Houston Internal Medicine and Pediatric Center- Site Number : 8400025
🇺🇸Tomball, Texas, United States
Kaiser Permanente - Santa Clara- Site Number : 8400061
🇺🇸Santa Clara, California, United States
PAS Research- Site Number : 8400049
🇺🇸Henderson, Nevada, United States
Northwest Arkansas Pediatric Clinic- Site Number : 8400002
🇺🇸Fayetteville, Arkansas, United States
Matrix Clinical Research - Los Angeles- Site Number : 8400008
🇺🇸Los Angeles, California, United States
Summerwood Pediatrics- Site Number : 8400021
🇺🇸Liverpool, New York, United States
SUNY Upstate Medical University - Syracuse- Site Number : 8400029
🇺🇸Syracuse, New York, United States
Cyn3rgy Research- Site Number : 8400053
🇺🇸Gresham, Oregon, United States
Utah Valley Pediatrics - Orem- Site Number : 8400067
🇺🇸Orem, Utah, United States
Investigational Site Number : 6300003
🇵🇷Ponce, Puerto Rico
Integrated Clinical Research- Site Number : 8400036
🇺🇸Tarzana, California, United States
Riveldi Biomedical Research and Associates - Miami- Site Number : 8400015
🇺🇸Miami, Florida, United States
SEC Clinical Research- Site Number : 8400034
🇺🇸Pensacola, Florida, United States
Velocity Clinical Researchâ€" New Orleans- Site Number : 8400058
🇺🇸New Orleans, Louisiana, United States
Midwest Childrens Health Research Institute- Site Number : 8400038
🇺🇸Lincoln, Nebraska, United States
Velocity Clinical Research - Omaha- Site Number : 8400001
🇺🇸Omaha, Nebraska, United States
Ventavia Research Group - Houston - North Loop West- Site Number : 8400010
🇺🇸Houston, Texas, United States
Alliance for Multispeciality Research - El Dorado- Site Number : 8400019
🇺🇸El Dorado, Kansas, United States
Pas Research - Pittsburgh- Site Number : 8400043
🇺🇸Pittsburgh, Pennsylvania, United States
Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003
🇺🇸Dallas, Texas, United States
Paradigm Clinical Research Centers- Site Number : 8400059
🇺🇸La Mesa, California, United States
The Medici Medical Research- Site Number : 8400055
🇺🇸Hollywood, Florida, United States
Dade Research Center- Site Number : 8400014
🇺🇸Miami, Florida, United States
Leavitt Women's Healthcare- Site Number : 8400009
🇺🇸Idaho Falls, Idaho, United States
Ventavia Research Group - Fort Worth- Site Number : 8400020
🇺🇸Fort Worth, Texas, United States
Chemidox Clinical Trials- Site Number : 8400039
🇺🇸Houston, Texas, United States
Research Your Health- Site Number : 8400066
🇺🇸Plano, Texas, United States
Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056
🇺🇸Pleasant View, Utah, United States
Investigational Site Number : 6300001
🇵🇷Caguas, Puerto Rico
Investigational Site Number : 4840001
🇲🇽Mexico City, Ciudad De Mexico, Mexico
Investigational Site Number : 4840002
🇲🇽Temixco, Morelos, Mexico